Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
暂无分享,去创建一个
A. Schneeweiss | C. Denkert | A. Buzdar | W. Eiermann | A. Makris | R. Souchon | S. Loibl | M. Untch | H. Bonnefoi | P. Mcgale | H. Bear | J. Pierga | G. von Minckwitz | V. Stearns | M. Kaufmann | W. Miller | M. Colleoni | G. Minckwitz | V. Semiglazov | W. Miller | C. Denkert | R. Jackesz
[1] Michael Gnant,et al. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF , 2007, Breast Cancer Research and Treatment.
[2] A. Luini,et al. Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer. , 2007, Breast.
[3] G. von Minckwitz,et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. , 2007, Breast.
[4] Ludovic Ferrer,et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Bonomo,et al. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. , 2006, Clinical radiology.
[6] S. Singletary,et al. Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy , 2006, Annals of Surgical Oncology.
[7] S. Loibl,et al. Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial , 2006, Annals of Surgical Oncology.
[8] J. Ross,et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Chérel,et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] H. Kuerer,et al. Meta‐analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer , 2006, The British journal of surgery.
[11] Roland Eils,et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Musolino,et al. Evaluation of HER-2/Neu Amplification and Other Biological Markers as Predictors of Response to Neoadjuvant Anthracycline-Based Chemotherapy in Primary Breast Cancer: The Role of Anthracycline Dose Intensity , 2006, American journal of clinical oncology.
[13] T. Karn,et al. Gene Expression Profiles of Breast Cancer Obtained from Core Cut Biopsies Before Neoadjuvant Docetaxel, Adriamycin, and Cyclophoshamide Chemotherapy Correlate with Routine Prognostic Markers and Could Be Used to Identify Predictive Signatures , 2005, Zentralblatt fur Gynakologie.
[14] L. Carey,et al. Size of Residual Lymph Node Metastasis After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients Is Prognostic , 2006, Annals of Surgical Oncology.
[15] Yoshinobu Sato,et al. Preoperative Evaluation of Residual Tumor Extent by Three‐Dimensional Magnetic Resonance Imaging in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy , 2006, The breast journal.
[16] L. Turnbull,et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy , 2006, British Journal of Cancer.
[17] S. Singletary,et al. Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy , 2006, Annals of surgery.
[18] Alan Ashworth,et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance , 2006, Breast Cancer Research and Treatment.
[19] I. Smith,et al. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma , 2006, British Journal of Cancer.
[20] G. Hortobagyi,et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Collins,et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[22] F. Penault-Llorca,et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer , 2005, Breast Cancer Research and Treatment.
[23] E. Winer,et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Dowsett,et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Cruz,et al. HER‐2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma , 2005, Cancer.
[26] H. Ashamalla,et al. Correlation of cytokine levels and response to radiation therapy and/or brachytherapy in low/intermediate risk prostate cancer , 2005 .
[27] M. J. van de Vijver,et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] T. Julian,et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Blohmer,et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] B. Kaufman,et al. Breast Conservation After Neoadjuvant Chemotherapy , 2005, Annals of Surgical Oncology.
[31] M. Gnant,et al. Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer , 2005, Anti-cancer drugs.
[32] Y. Boucher,et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] G. Hortobagyi,et al. Breast conservation after neoadjuvant chemotherapy , 2005, Cancer.
[34] Diethelm Wallwiener,et al. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance , 2005, Cancer.
[35] Shinzaburo Noguchi,et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Blohmer,et al. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial , 2005, Anti-cancer drugs.
[37] A. Makris,et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer , 2004, British Journal of Cancer.
[38] A. Schneeweiss,et al. Neoadjuvant therapy with gemcitabine in breast cancer. , 2004, Oncology.
[39] S. Lakhani,et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer , 2004, British Journal of Cancer.
[40] D. Mankoff,et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. , 2004, Academic radiology.
[41] Roman Rouzier,et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] A. El-Khoueiry,et al. Adjuvant gemcitabine and cisplatin (GC) for locally advanced cancer of the bladder after radical cystectomy: A USC experience with molecular correlates , 2004 .
[43] J. Stec,et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] G. Hortobagyi,et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] D. Generali,et al. Magnetic Resonance Imaging in Comparison to Clinical Palpation in Assessing the Response of Breast Cancer to Epirubicin Primary Chemotherapy , 2004, Breast Cancer Research and Treatment.
[46] Claudio Landoni,et al. PET/CT and breast cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[47] A. Garg,et al. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. , 2004, International journal of radiation oncology, biology, physics.
[48] W. Allum,et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Syed Mohsin,et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.
[50] J. Coindre,et al. DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer , 2003, British Journal of Cancer.
[51] Hans-Peter Sinn,et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Stephan E Maier,et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Ying Lu,et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. , 2002, AJR. American journal of roentgenology.
[54] M. Brizzi,et al. Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease , 2001, Breast Cancer Research and Treatment.
[55] H. Tsuda,et al. Accuracy of contrast‐enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy , 2001, International journal of cancer.
[56] G. Hortobagyi,et al. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[57] A. Tulpule,et al. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] R. Given-Wilson,et al. The use of ultrasound for monitoring breast tumour response to pro-adjuvant therapy. , 1994, Clinical radiology.
[59] U. Chetty,et al. Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment , 1994, The British journal of surgery.
[60] B. Asselain,et al. Neoadjuvant chemotherapy in operable breast cancer. , 1991, European journal of cancer.
[61] L. Boni,et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[62] D. Mankoff,et al. Changes in Glucose Metabolism and Blood Flow Following Chemotherapy for Breast Cancer. , 2006, PET clinics.
[63] D. Berry. Chemotherapy is More Effective in Patients With Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment , 2006 .
[64] F. Penault-Llorca,et al. High Prognostic Significance of Residual Disease After Neoadjuvant Chemotherapy: a Retrospective Study in 710 Patients with Operable Breast Cancer , 2006, Breast Cancer Research and Treatment.
[65] M. Morrow. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27 , 2006 .
[66] G. Hortobagyi,et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] I. Zuna,et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution , 2002, European Radiology.
[68] L. Esserman,et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] J. Affeldt,et al. The feasibility study , 2019, The Information System Consultant’s Handbook.